Preventing Dyspnea During Speech in Older Speakers
24. juni 2022 oppdatert av: Maude Desjardins, University of Delaware
Self-Regulated Airflow Management in Daily Communicative Activities to Prevent Dyspnea During Speech in Older Speakers
Due to various comorbidities affecting the respiratory system, older speakers are at risk of experiencing breathing discomfort (dyspnea) during high-demand vocal activities such as singing, loud speaking, and speaking while exercising. Dyspnea during speech can promote avoidance of certain situations involving voice production, thus leading to vocal deconditioning and decreased quality of life. The goal of this pilot study is to test the feasibility and acceptability of a 4-week remote group intervention targeting phonatory dyspnea, and to gather preliminary efficacy data.
Participants will receive an intervention including a 2-week socialization phase (control condition) and a 4-week speech breathing intervention phase (experimental condition). Both phases will be delivered remotely and in a group setting (10 participants per group).
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
20
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
- University of Delaware
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
50 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- sign the informed consent form
- report dyspnea in at least one of the items of the University of Cincinnati Dyspnea Questionnaire referring to speech
- be available during the dates of the scheduled group interventions
- be aged 50 years or older
Exclusion Criteria:
- do not have access to a computer and internet connection
- present with a known voice pathology (other than age-related vocal fold atrophy) and/or are receiving speech therapy at the time of the study
- have a known neurodegenerative disease affecting speech/voice
- are a current smoker
- are receiving pulmonary rehabilitation at the time of the study or are starting a new medication regimen for a respiratory disease at the time of study onset;
- have a hearing loss that is not adequately managed, as judged by the Principal Investigator (PI)
- have professional vocal training [amateur choir singers will not be excluded]
- cannot provide informed consent or easily follow instructions
- have any other condition that precludes them from participating in the behavioral interventions, as judged by the PI.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: All participants
This is a single-arm trial.
All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks).
Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
|
Control condition: does not involve speech-related exercises
Experimental condition: involves speech-related exercises
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in reported dyspnea
Tidsramme: Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
Participant self-ratings of dyspnea on the University of Cincinnati Dyspnea Questionnaire.
This questionnaire contains 30 items scored on a Likert scale ranging from 1 (not at all short of breath) to 5 (always short of breath or cannot do).
A higher scores indicates greater shortness of breath and therefore greater handicap.
|
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
|
Change in reported voice handicap
Tidsramme: Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
Participant self-ratings of voice handicap on the Voice Handicap Index-10.
The Voice Handicap Index-10 is an ordinal scale that measures the degree of handicap a person experiences because of their voice disorder.
Each item is scored on a Likert scale ranging from 0 to 4. The minimum score is 0 and the maximal score 40.
A higher score indicates a greater perceived voice handicap.
|
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in reported self-efficacy
Tidsramme: Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
Participant self-ratings of self-efficacy for managing their symptoms, using the Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy Questionnaire - Managing Symptoms.
This questionnaire contains 28 items, each scored on a Likert scale ranging from 1 (I am not at all confident) to 5 (I am very confident).
A higher score indicates a greater self-efficacy.
|
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
|
|
Acceptability of the intervention
Tidsramme: Assessed after the 4-week experimental condition, at the end of the study period.
|
Participants' perceived acceptability of the intervention using the Acceptability of Intervention Measure.
This questionnaire contains 5 items scored on a Likert scale ranging from 1 (completely disagree) to 5 (completely agree).
A higher score indicates a greater acceptability.
|
Assessed after the 4-week experimental condition, at the end of the study period.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. september 2021
Primær fullføring (Faktiske)
10. mars 2022
Studiet fullført (Faktiske)
10. mars 2022
Datoer for studieregistrering
Først innsendt
29. august 2021
Først innsendt som oppfylte QC-kriteriene
29. august 2021
Først lagt ut (Faktiske)
1. september 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. juni 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. juni 2022
Sist bekreftet
1. juni 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1767412
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .